Results 101 to 110 of about 20,705 (157)

Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study. [PDF]

Int J Chron Obstruct Pulmon Dis, 2023
Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N, Pollack M.   +11 more
europepmc   +1 more source

The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN). [PDF]

Respir Res, 2023
Skloot GS, Guasconi A, Lavon BR, Georges G, De Backer W, Galkin D, Cortellini M, Panni I, Bates JHT.   +8 more
europepmc   +1 more source

Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD

, 2018
Colin Reisner,1,2 James Pearle,3 Edward M Kerwin,4 Earl St Rose,1 Patrick Darken1 1Pearl – a member of the AstraZeneca Group, Morristown, NJ, USA; 2AstraZeneca, Gaithersburg, MD, USA; 3California Research Medical Group, Inc., Fullerton, CA, USA ...
Kerwin EM, Darken P, Reisner C, Pearle J, St Rose E   +4 more
core  

Budesonide/formoterol fumarate dihydrate <i>versus</i> budesonide with a novel suspension technology for uncontrolled asthma: phase 3 VATHOS study. [PDF]

ERJ Open Res
Jackson DJ, Wise RA, Papi A, Lugogo N, Chen R, Chami H, Armengol C, Daoud SZ, Nauclér E, Bowen K, Megally A, Sobande O, Patel M.   +12 more
europepmc   +1 more source

Budesonide/formoterol fumarate dihydrate <i>versus</i> budesonide with a novel suspension technology for uncontrolled asthma: phase 3 LITHOS study. [PDF]

ERJ Open Res
Papi A, Wise RA, Jackson DJ, Lugogo N, Chen R, Chami H, Armengol C, Daoud SZ, Nauclér E, Bowen K, Megally A, Sobande O, Patel M.   +12 more
europepmc   +1 more source

Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease. [PDF]

Ther Adv Respir Dis, 2023
Pelaia C, Procopio G, Rotundo FL, Deodato MR, Ferrante Bannera A, Tropea FG, Cancelliere A, Vatrella A, Pelaia G.   +8 more
europepmc   +1 more source

Real-World Outcomes across Baseline Risk Profiles in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate in Spain: Insights from the ORESTES Study. [PDF]

Pulm Ther
Alcázar-Navarrete B, Figueira-Gonçalves JM, Blanco Cid N, Bruguera Avila N, Bernabeu Mora R, Fuster Gomila A, Galera Martínez R, García Clemente MM, Granados G, Khadour Khadour H, Márquez-Martín E, Murga Arizabaleta I, Velasco Garrido JL, Corregidor-García C, Fitas E, Sánchez-Covisa J.   +15 more
europepmc   +1 more source

Quantitative Determination of Related Substances in Formoterol Fumarate and Tiotropium in Tiomate Transcaps^® Dry Powder Inhaler [PDF]

Turk J Pharm Sci, 2022
Gondhale PS, Varghese Cheriyan B.
europepmc   +1 more source

Letter to the Editor Regarding "Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study". [PDF]

Adv Ther
Golpe R.
europepmc   +1 more source

Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain. [PDF]

Int J Chron Obstruct Pulmon Dis, 2022
Trigueros JA, Garin N, Baloira A, Aceituno S, Calvo A, Prades M, Touron C, Martínez A, Torres C.   +8 more
europepmc   +1 more source